National Cancer Institute; Notice of Closed Meetings, 42559 [2017-19026]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 173 / Friday, September 8, 2017 / Notices
go/connectpro_overview. FDA has
verified the Web site addresses in this
document, as of the date this document
publishes in the Federal Register, but
Web sites are subject to change over
time.
Transcripts: Please be advised that as
soon as a transcript of the public
workshop is available, it will be
accessible at https://
www.regulations.gov. It may be viewed
at the Dockets Management Staff (see
ADDRESSES). A link to the transcript will
also be available on the Internet at
https://www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm.
IV. References
The following references are on
display in the Dockets Management
Staff (see ADDRESSES) and are available
for viewing by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday; they are also available
electronically at https://
www.regulations.gov. FDA has verified
the Web site addresses, as of the date
this document publishes in the Federal
Register, but Web sites are subject to
change over time.
1. National Cancer Institute, ‘‘Cancer Stat
Facts: Cervix Uteri Cancer,’’ (https://
seer.cancer.gov/statfacts/html/
cervix.html).
2. Horner, M.J., S.F. Altekruse, Z. Zou, L.
Wideroff, et al. ‘‘U.S. Geographic
Distribution of Pre-Vaccine Era Cervical
Cancer Screening, Incidence, Stage, and
Mortality.’’ Cancer Epidemiology,
Biomarkers & Prevention. 2011 Jan.;
20(4):591–9. doi: 10.1158/1055–9965.
EPI–10–1183.
3. Freeman, H.W.B. ‘‘Excess Cervical Cancer
Mortality: A Marker for Low Access to
Health Care in Poor Communities.’’
Rockville (MD): National Cancer
Institute, Center to Reduce Cancer Health
Disparities; 2005.
Dated: September 1, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
sradovich on DSK3GMQ082PROD with NOTICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the NHLBI Special Emphasis
Panel.
Jkt 241001
Dated: September 1, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–19027 Filed 9–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Pancreatic
Cancer Detection Consortium (U01).
Date: November 3, 2017.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W240, Rockville, MD 20850, (Telephone
Conferece Call).
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240, Bethesda, MD
20892–9750, 240–276–5122, hasan.siddiqui@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Cooperative Agreement To Develop Targeted
Agents Used With Systemic Agents Plus
Radiotherapy.
Date: November 17, 2017.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, MD 20850, (Telephone
Conferece Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W640, Bethesda, MD 20892–9750,
240–276–7684, saejeong.kim@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: September 1, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–19026 Filed 9–7–17; 8:45 am]
National Cancer Institute; Notice of
Closed Meetings
BILLING CODE 4164–01–P
17:18 Sep 07, 2017
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Resources for Clinical Trials.
Date: September 20, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7200, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Michael P. Reilly, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7200, Bethesda, MD 20892, 301–827–7975,
reillymp@nhlbi.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
National Institutes of Health
[FR Doc. 2017–19029 Filed 9–7–17; 8:45 am]
VerDate Sep<11>2014
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
42559
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
National Institutes of Health
Proposed Collection; 30-Day Comment
Request; Application To Participate in
the National Institutes of Health
Technical Assistance Programs:
Commercialization Accelerator
Program (CAP)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
E:\FR\FM\08SEN1.SGM
Notice.
08SEN1
]]>Agencies
[Federal Register Volume 82, Number 173 (Friday, September 8, 2017)]
[Notices]
[Page 42559]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19026]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Pancreatic Cancer Detection Consortium (U01).
Date: November 3, 2017.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, 9609 Medical
Center Drive, Room 7W240, Rockville, MD 20850, (Telephone Conferece
Call).
Contact Person: Hasan Siddiqui, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W240, Bethesda, MD 20892-9750, 240-276-5122,
hasan.siddiqui@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Cooperative Agreement To Develop Targeted Agents Used With
Systemic Agents Plus Radiotherapy.
Date: November 17, 2017.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute, Shady Grove, 9609 Medical
Center Drive, Room 7W640, Rockville, MD 20850, (Telephone Conferece
Call).
Contact Person: Saejeong J. Kim, Ph.D., Scientific Review
Officer, Resources and Training Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Bethesda, MD 20892-9750, 240-276-7684,
saejeong.kim@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: September 1, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-19026 Filed 9-7-17; 8:45 am]
BILLING CODE 4140-01-P
